

# The *ASXL1* mutation p.Gly646Trpfs\*12 found in a Turkish boy with Bohring-Opitz Syndrome

Roser Urreiziti<sup>1</sup> | Semra Gürsoy<sup>2</sup> | Laura Castilla-Vallmanya<sup>1</sup> | Guillem Cunill<sup>1</sup> | Raquel Rabionet<sup>1</sup> | Derya Erçal<sup>2</sup> | Daniel Grinberg<sup>1</sup> | Susana Balcells<sup>1</sup>

<sup>1</sup>Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, IBUB, IRSJD, CIBERER, Barcelona, Spain

<sup>2</sup>Department of Pediatric Genetics, Dokuz Eylül University, İzmir, Turkey

## Correspondence

Roser Urreiziti, Department of Genetics, Microbiology and Statistics, Faculty of Biology, UB. Avda Diagonal, 643, E-08028, Barcelona, Spain.  
Email: urreiziti@ub.edu

## Funding information

Associació Síndrome Opitz C, Terrassa, Spain; Agència de Gestió d'Ajuts Universitaris i de Recerca, Grant/Award Number: 2014SGR932; CIBERER, Grant/Award Number: U720; Secretaría de Estado de Investigación, Desarrollo e Innovación, Spanish Ministerio de Economía y Competitividad, Grant/Award Number: SAF2016-75948-R; FECYT; crowdfunding PRECIPITA; Generalitat de Catalunya, Grant/Award Number: PERIS 2016-20

## Key Clinical Message

In line with a recent study showing that *ASXL1* mutations found in the common population cannot be ruled out as pathogenic, we have identified the *ASXL1* p.Gly646Trpfs\*12 mutation—present in 132 individuals in ExAC—as a very probable cause of the disease in a Bohring-Opitz syndrome patient.

## KEYWORDS

*ASXL1*, Bohring-Opitz syndrome, intellectual disability, mutation prioritization, variants of unknown significance

## 1 | INTRODUCTION

Bohring-Opitz syndrome (BOS, MIM #605039) is a rare and severe disease characterized mainly by intrauterine growth retardation, feeding difficulties, severe to profound developmental delay, nonspecific brain abnormalities, microcephaly, flexion at the elbows with ulnar deviation and flexion of the wrists and metacarpophalangeal joints (known as BOS posture) and distinctive facial features.<sup>1</sup> Heterozygous *ASXL1* truncating mutations have been identified as the main cause of BOS.<sup>1,2</sup> A recent publication<sup>3</sup> called the attention to the

fact that mutations associated with BOS are also present in the ExAC (Exome Aggregation Consortium) database.<sup>4</sup> As *ASXL1* is one of the genes most commonly mutated during hematopoietic clonal expansion of cells, the authors hypothesized that the presence of this mutation in public databases could be due to somatic mosaicism, and they could confirm the hypothesis by manual examination of the ExAC WES reads.

We have recently identified a new BOS case, in which Sanger sequencing of *ASXL1* revealed the p.Gly646Trpfs\*12 mutation, also present in ExAC.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2018 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd.

## 2 | CASE REPORT

The patient is a 4-year-old Turkish boy, only child of a healthy nonconsanguineous couple and born at term via normal vaginal delivery after an uneventful pregnancy. The birthweight was 2.3 kg (1st percentile,  $-2.4$  SD), height was 45 cm ( $-2.3$  SD), and head circumference was 32 cm (4th percentile,  $-1.7$  SD). The patient was referred to the genetics department at the 9th day of life. Physical examination revealed trigonocephaly, microcephaly, nevus simplex (flammeus), dysmorphic features, intrauterine growth retardation, and BOS posture with fixed contractures. In the postnatal period, the patient was intubated due to respiratory problems. As he could not be extubated, at 4 months tracheostomy was performed. He was fed through G tube since the 4th month of life. At 2 months of age, the patient started suffering seizures. Abnormalities were detected by EEG, and antiepileptic treatment with levetiracetam and phenobarbital was initiated. Seizures have been under control thereafter with 3-4 attacks annually of a very short duration.

At 15 months, his weight was 10 kg (24th percentile,  $-0.69$  SD), height was 62 cm ( $<3$ rd percentile,  $-5.4$  SD), and head circumference was 41.5 cm ( $<1$ st percentile,  $-4.25$

SD). At 3.5 years, he had microcephaly (45.5 cm;  $<3$ rd percentile,  $-2.43$  SD), trigonocephaly, up-slanting palpebral fissures, narrow forehead, nevus simplex, hypertrichosis, low-set ears, low frontal hairline, microretrognathia, high palate and delayed teeth eruption (no eruption at 3 years of age; Figure 1A,B). He also had bilateral cryptorchidism and brachydactyly (Figure 1C), as well as hypotonia and spasticity on both his upper and lower extremities. In particular, the patient had contractures of the hands and fingers. Additionally, overlapping toes were detected in the feet (Figure 1D). Cranial magnetic resonance revealed corpus callosum agenesis and atrophy of the optic nerve, and he failed the hearing test bilaterally. The patient also underwent echocardiography, which revealed a small patent ductus arteriosus. Abdominal ultrasound and metabolic tests were normal. The patient's developmental milestones were severely delayed (he was not able to sit, crawl or walk independently and he was not able to speak). His karyotype and aCGH results were normal.

After reviewing the clinical presentation of the patient, Bohring-Opitz syndrome was suspected, and the *ASXL1* gene was manually sequenced. Written informed consent from the patient's family was obtained, and all protocols were approved by the Ethics Committee of the Universitat de Barcelona (IRB00003099). A *de novo* heterozygous



**FIGURE 1** Facial, hand and foot phenotypes of the patient at 3 y of age. A and B, Facial dysmorphisms, especially trigonocephaly and nevus simplex (flammeus) is clearly appreciated. C, brachydactyly is appreciable in the patient's hand. D, Foot phenotype with overlapping toes

mutation, c.1934dupG (p.Gly646Trpfs\*12), was identified. The PCR amplification and Sanger sequencing were repeated twice, independently and the PCR fragment was cloned and sequenced (see Figure S1) to unequivocally confirm the mutation.

### 3 | DISCUSSION

While the clinical outcome of the patient clearly pointed to a Bohring-Opitz Syndrome, the fact that he was carrying a mutation (p.Gly646Trpfs\*12) present in 132 individuals from the general population hindered taking a final decision on the genetic diagnosis. In this sense, other mutations present in ExAC (among them the p.Arg404Ter described by Carlston et al<sup>3</sup>) were previously found to be BOS -causing (Table 1). The p.Gly646Trpfs\*12 mutation described in our BOS case

is one of the two *ASXL1* loss of function (LoF) changes especially frequent in ExAC, the other being p.Gly645Valfs\*58 (found in 118 individuals). Both changes are located in an eight-nucleotide G-homopolymer tract and could be over-represented due to sequencing errors. While these changes were not included in Carlston et al<sup>3</sup> analyses, the authors discussed the fact that the p.Gly646Trpfs\*12 mutation had been identified in a large series of myeloid malignancies by deep sequencing (confirmed by manual methods in some cases) and had been described as the most common cancer-associated *ASXL1* mutation.<sup>5</sup> Besides, 66% of the ExAC carriers of the p.Gly646Trpfs\*12 mutation belong to the Cancer Genome Atlas (TCGA) population.

This mutation is a truncating mutation affecting the last exons of the *ASXL1* gene, similarly to all the previously described BOS mutations (Figure 2). More recently, the p.Gly646Trpfs\*12 mutation has been filtered from the GnomAD

**TABLE 1** BOS-causing *ASXL1* mutations present in ExAC

cDNA mutation	Prot. mutation	Reported phenotype	ExAc	GenomAD	Origen
c.1117C>T	p.Q373*	Focal Epilepsy <sup>a</sup>	no	2/246256	6
c.1129C>T	p.Q377*	ID <sup>a</sup>	no	no	7
c.1210C>T	p.R404*	Bohring-Opitz syndrome	7/121378	4/246248	2, 3, 8, 9
c.1269dupT	p.L424fs	Bohring-Opitz syndrome	no	no	10
c.1272_1273delGT	p.T425Qfs*12	Bohring-Opitz syndrome	no	1/246262	1
c.1544_1545delTG	p.V515Gfs*13	Focal Epilepsy <sup>a</sup>	no	no	6
c.1924 G>T	p.G642*	Bohring-Opitz syndrome	no	no	1
c.1934insG	<b>p.G646Wfs*12</b>	Bohring-Opitz syndrome	132/80804	no <sup>b</sup>	<b>Present study</b>
c.2013_2014 del	p.C672Tfs*4	Bohring-Opitz syndrome	no	no	1
c.2036_2037insG	p.G680Rfs*38	Bohring-Opitz syndrome	no	no	11
c.2100dupT	p.P701Sfs*16	Bohring-Opitz syndrome	no	no	12
c.2197C>T	p.Q733*	Bohring-Opitz syndrome	1/121070 <sup>c</sup>	idem ExAC	2
c.2324 T>G,	p.L775*	Bohring-Opitz syndrome	1/121162	no <sup>b</sup>	1
c.2332C>T	p.Q778*	Bohring-Opitz syndrome	no	no	2
c.2407_2411del5	p.Q803Tfs*17	Bohring-Opitz syndrome	3/120748 <sup>c</sup>	no <sup>b,c</sup>	2
c.2468T>G	p.L823*	Bohring-Opitz syndrome	2/120758 <sup>c</sup>	2/244338 <sup>c</sup>	2
c.2535dup	p.S846Qfs*5	Bohring-Opitz syndrome	no	no	1
c.2759_2762dup	p.V922Ifs*3	Bohring-Opitz syndrome	no	no	1
c.2773C>T	p.Q925*	Bohring-Opitz syndrome	no	no	2
c.2893C>T	p.R965*	Bohring-Opitz syndrome	1/121306	3/246200	13
c.3077del	p.G1026Dfs*21	Bohring-Opitz syndrome	no	no	1
c.3083C>A	p.S1028*	Bohring-Opitz syndrome	no	no	2
c.4060 G>T	p.E1354*	Bohring-Opitz syndrome	no	no	14
c.4116_4117del2	p.F1373fs	Bohring-Opitz syndrome <sup>d</sup>	no	no	15


<sup>a</sup>Clinical history is limited without description of presence or absence of other BOS features.

<sup>b</sup>Filtered in GenomAD (failed random forest filters).

<sup>c</sup>These numbers correspond to another mutation affecting the same residue.

<sup>d</sup>The patient is also carrying recessive mutations in the CFTR gene.

Bold type indicates the mutation in the case presented here



**FIGURE 2** ASXL1 protein structure and BOS-causing mutations. In italics, mutations also present in ExAC. ASXL1 coding exons are indicated above. ASXN, ASX N-terminal domain; NLS, Nuclear localization signal; ASXM, ASX middle domains; PHD, plant homeodomain

database as it failed random forest filters. In addition, very recently a new patient with this mutation was reported to ClinVar by GenDX, although the clinical outcome of the patient was not reported.

Taking all this into consideration, we conclude that the p.Gly646Trpfs\*12 mutation is a disease-causing mutation responsible for the patient's BOS clinical presentation and that, as Carlston et al<sup>3</sup> stated, the assumption that pathogenic variants in genes associated with severe, pediatric-onset, highly penetrant, autosomal dominant conditions have to be absent or extremely rare in public databases has to be taken cautiously.

## ACKNOWLEDGMENTS

The authors thank the patient and his family for their wholehearted collaboration. They are also grateful to M. Cozar for technical assistance. Funding was from Associació Síndrome Opitz C, Terrassa, Spain; Spanish Ministerio de Economía y Competitividad (SAF2016-75948-R; FECYT, crowdfunding PRECIPITA), Catalan Government (2014SGR932) and from CIBERER (U720). RR is a postdoctoral fellow under the PERIS 2016-20 program of Generalitat de Catalunya. The authors declare no competing financial interests.

## AUTHOR CONTRIBUTION

RU, SG, DG, and SB: contributed to the planning of this work. RU, SG, LCV, GC, RR, DE, DG, and SB: conducted this work. RU, LCV, and GC: performed the sequencing, cloning, and chromatogram analysis. RU and RR: performed the bibliographical, in silico and database analysis of the mutation. SG and DE: clinically evaluated the patient and have generated and written the clinical data. RU, SB, and DG: wrote the main manuscript text. RU and RR: elaborated

Table 1. RU and SG: prepared Figure 1. RU, SB, and DG: prepared Figure 2. RU and GC: prepared Figure S1. All authors reviewed the manuscript.

## CONFLICT OF INTEREST

None declared.

## ORCID

Roser Urreizti  <http://orcid.org/0000-0003-3617-7134>

## REFERENCES

- Russell B, Johnston JJ, Biesecker LG, et al. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance. *Am J Med Genet A*. 2015;167A:2122-2131.
- Hoischen A, van Bon BW, Rodriguez-Santiago B, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. *Nat Genet*. 2011;43:729-731.
- Carlston CM, O'Donnell-Luria AH, Underhill HR, et al. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. *Hum Mutat*. 2017;38:517-523.
- Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536:285-291.
- Van Ness M, Szankasi P, Frizzell K, Shen W, Kelley TW. Analysis of ASXL1 mutations in a large series of myeloid malignancies. *Mod Pathol*. 2016;29(Suppl. 2):333-388.
- Helbig KL, Farwell Hagman KD, Shinde DN, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. *Genet Med*. 2016;18:898-905.
- Grozeva D, Carss K, Spasic-Boskovic O, et al. Targeted next-generation sequencing analysis of 1,000 individuals with intellectual disability. *Hum Mutat*. 2015;36:1197-1204.

8. Asaleh Y. Bohring-Opitz syndrome in Libya. *Libyan J Med Res.* 2014;8:47-49.
9. Zhu X, Petrovski S, Xie P, et al. Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. *Genet Med.* 2015;17:774-781.
10. Brunelli L, Mao R, Jenkins SM, et al. A rapid gene sequencing panel strategy to facilitate precision neonatal medicine. *Am J Med Genet A.* 2017;173A:1979-1982.
11. Arunachal G, Danda S, Omprakash S, Kumar S. A novel de-novo frameshift mutation of the ASXL1 gene in a classic case of Bohring-Opitz syndrome. *Clin Dysmorphol.* 2016;25:101-105.
12. Urreizti R, Roca-Ayats N, Trepal J, et al. Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes. *Am J Med Genet A.* 2016;170A:24-31.
13. Magini P, Della Monica M, Uzielli ML. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations. *Am J Med Genet A.* 2012;158A:917-921.
14. Srivastava S, Cohen JS, Vernon H, et al. Clinical whole exome sequencing in child neurology practice. *Ann Neurol.* 2014;76:473-483.
15. Dangiolo SB, Wilson A, Jobanputra V, Anyane-Yeboah K. Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: review of the most prevalent molecular and phenotypic features of the syndrome. *Am J Med Genet A.* 2015;167A:3161-3166.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Urreizti R, Gürsoy S, Castilla-Vallmanya L, et al. The ASXL1 mutation p. Gly646Trpfs\*12 found in a Turkish boy with Bohring-Opitz Syndrome. *Clin Case Rep.* 2018;6: 1452–1456. <https://doi.org/10.1002/ccr3.1603>